Spinal Muscular Atrophy Treatment Market Expected to Grow by 2030 | Major companies include – Novartis, Cytokinetics, Astellas, Biogen, Novartis, Roche, PTC Therapeutics and others
“Delveinsight LLP Commercial Research”
The “Spinal Muscular Atrophy Market Insights, Epidemiology and Market Forecast 2030” report from DelveInsight provides an in-depth understanding of the historical and predicted epidemiology as well as the United States Spinal Muscular Atrophy market size and share. United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Spinal Muscular Atrophy Market Report covers emerging drugs, current treatment practices, individual therapy market share, current and forecast market size from 2017 to 2030. It assesses current treatment practice / algorithm, market drivers, barriers market and unmet medical needs to organize the best of opportunities and assess the underlying potential of the market.
Spinal atrophy: an overview
According to the National Institute of Health (NIH), spinal muscular atrophy is a genetic disease characterized by weakness and atrophy (atrophy) of the muscles used for movement (skeletal muscles). It is caused by the loss of specialized nerve cells, called motor neurons, which control muscle movement. Weakness tends to be more severe in muscles that are close to the center of the body (proximal) compared to muscles that are far from the center of the body (distal). Muscle weakness usually gets worse with age.
ADS is a motor neuron disease caused by a biallelic mutation in the motor neuron survival gene 1 (SMN1). There are two identical genes SMN1 (telomeric copy) and SMN2 (centromeric copy) present on human chromosome 5q13. These genes are responsible for synthesizing the motor neuron survival protein that is necessary for the normal functioning of the motor neurons that control our muscles. Insufficient production of SMN proteins results in debilitating and often fatal muscle weakness.
Highlights of the Spinal Muscular Atrophy Market
Total spinal muscular atrophy (SMA) prevalent population in the seven main markets was 19,343 in 2017.
Among the EU5 countries, Germany was estimated to have the most prevalent population of spinal muscular atrophy with 1,643 cases in 2017, followed by the United Kingdom and France. In contrast, Spain had the lowest prevalence with 468 cases in 2017.
According to DelveInsight’s analysis, the diagnosis frequent cases of spinal muscular atrophy in the United States were 11,733 in 2017.
According to the study by B. Melissa et al. (2017), spinal muscular atrophy (SMA) is the most common genetic disease leading to death in infancy, affecting approximately 1 in 6,000 to 1 in 10 births. 000. Therapies that improve neuromuscular function and maintain the lifelong general health of people with ADS are therefore a major priority and an unmet clinical need.
Spinal muscular atrophy market
Approaches to the management of spinal muscular atrophy focus on nutrition, assessment of respiratory care, respiratory muscle weakness, orthopedic care, rehabilitation, as well as some medication. The vast research and development activities of pharmaceutical companies, along with the increasing prevalence are expected to fuel the growth of the market in the coming years.
The market outlook section of the report helps to understand in detail the historical, current and forecast Spinal Muscular Atrophy Market Size and Share by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and the demand for better technology.
The report details the Spinal muscular atrophy market trend of each drug marketed and therapy in the terminal phase by evaluating their impact according to the annual cost of the treatment, the inclusion and exclusion criteria, the mechanism of action, the increase in the number of patients, the patient segment coverage, planned launch year, competition with other therapies, brand value, their impact on the market and the views of key opinion leaders.
Request for sample @ Assessment of the spinal muscular atrophy therapeutic market
Epidemiology of spinal muscular atrophy
Epidemiology section covers overviews of history and current affairs Spinal muscular atrophy patient pool and predicted trends for seven major countries from 2017 to 2030. It helps recognize the causes of current and projected trends by exploring numerous studies and perspectives from key opinion leaders. The epidemiology section also provides the pool of patients diagnosed and their trends as well as the hypotheses adopted.
Spinal muscular atrophy drug uptake and pipeline development activities
The section on drug absorption focuses on the rate of absorption of potential drugs recently launched in the Spinal muscular atrophy market or is expected to be marketed during the study period. The analysis covers Drugs Spinal Muscular Atrophy Market Uptake; absorption of patients by therapies; and the sales of each drug.
The drug absorption section of the report helps to understand the drugs with the fastest absorption, the reasons for the maximum use of new drugs, and helps to compare drugs on the basis of market share and size. size, which will again be useful for studying the important factors in market absorption. and in financial and regulatory decision making.
The report also covers Spinal muscular atrophy pipeline development activities and provides valuable information on various phase II and phase III therapeutic candidates and on key market companies involved in the development of targeted therapies. It also analyzes recent developments such as collaborations, acquisitions and mergers, license patent details and other information on emerging therapies.
The Spinal Muscular Atrophy pipeline has several potential drugs in advanced and intermediate development that are expected to be launched in the near future.
Some of the key companies that are developing therapies for the treatment of spinal muscular atrophy include:
And many more.
Spinal muscular atrophy therapies covered in the report include:
And a few others.
Request a copy at: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight
1. Key information
2. Executive summary
3. Competitive intelligence analysis of spinal muscular atrophy
4.Spinal Muscular Atrophy Market Overview at a Glance
5. Background and overview of spinal muscular atrophy disease
6. Pathways of patients with spinal muscular atrophy
7. Spinal muscular atrophy epidemiology and patient population
8. Spinal muscular atrophy treatment algorithm, current treatment and medical practices
9. Spinal muscular atrophy Unmet needs
10. Main endpoints for treatment of spinal muscular atrophy
11. Products marketed for spinal muscular atrophy
12. Emerging therapies for spinal muscular atrophy
13. Major Market Analysis of Seven Spinal Muscular Atrophy
14. Attribute analysis
15. Spinal Muscular Atrophy Market Outlook (7 major markets)
16. Overview of access and reimbursement for spinal muscular atrophy
17. KOL’s Opinions on the Spinal Muscular Atrophy Market.
18. Spinal Muscular Atrophy Market Drivers
19. Barriers to the Spinal Muscular Atrophy Market
21. Capabilities of DelveInsight
* The table of contents is not exhaustive; final content may vary.
Get FREE sample at: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight
Latest DelveInsight Reports
Spinal muscular atrophy (SMA) pipeline overview
Spinal Muscular Atrophy (SMA) Pipeline Insight, DelveInsight 2021 report presents comprehensive information on the current clinical development scenario and growth prospects in the Spinal Muscular Atrophy (SMA) market.
Global Kinase Inhibitor In Autoimmune Disease Market
The “Global Kinase Inhibitor in Autoimmune Diseases Market Insights, Epidemiology, and Market Forecast 2030” report from DelveInsight provides an in-depth understanding of the size, actions and trends of the Global Kinase Inhibitor in Autoimmune Diseases market in the 7MM (i.e. ie the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan).
DelveInsight is a leading business consultant and market research firm focused exclusively on the life sciences. It supports pharmaceutical companies by providing them with complete end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact: Shruti Thakur
E-mail: Send an email
Address:304, boulevard S. Jones # 2432
State: new York
Country: United States